Organization and Nature of Operations (Details Narrative) - USD ($) $ / shares in Units, $ in Millions		9 Months Ended
	Jul. 15, 2024	Sep. 30, 2024	Dec. 31, 2023
Cash flows used in operating activities		$ 6.4
Common Stock, shares authorized		30,000,000	300,000,000
Common stock, Par value		$ 0.0001	$ 0.0001
Cash and cash equivalents		$ 1.3
Accumulated deficit		(287.0)
Reverse Stock Split [Member]
Common Stock, shares authorized	30,000,000
Common stock, Par value	$ 0.0001
Effected reverse stock split shares	10
Non assessable share of common stock, per share	$ 0.0001
Related Party Notes [Member]
Short-term promissory notes		$ 1.5
Interest Rate		8.00%
September 2024 Public Offering [Member]
Common Stock Units		805,900
Pre-Funded Units		2,773,000
Gross proceeds		$ 3.6
Equity Offerings Costs		$ 1.0
2024 Inducement Offer [Member]
Description of warrant inducement		such warrant holders immediately exercised up to an aggregate of (i) 33,160.8 Series E Warrants, (ii) 499,909.34 Series F Warrants, (iii) 499,909.34 Series G Warrants, (iv) 1,990,000 Series H Warrants, and (v) 2,325,000 Series I Warrants (collectively the “Existing Warrants”) to purchase up to approximately 5.3 million shares of the Company’s Common Stock at a reduced exercise price of $0.70 per share. In consideration for the immediate exercise of the Existing Warrants for cash, the Company agreed to issue unregistered new Series K Common Stock Purchase Warrants (“Series K Warrants”) to purchase up to 10.7 million shares of common stock. The Company expects to receive aggregate gross proceeds of approximately $3.7 million in cash from the exercise of these warrants pursuant to the 2024 Inducement Offer, prior to deducting placement agent fees and offering expense of $0.4 million. As of the date of the 2024 Inducement Offer, 578,900 Series H and 1,078,900 Series I warrants remained unexercised. As additional consideration, the Company issued placement agent warrants to purchase up to 320,879 shares of common stock on the same terms as the Series K warrants, except the exercise price is $1.085 per share and have a termination date of October 28, 2029